Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,477.16
(
-1.74%
)
US TECH 100
23,026.59
(
-2.07%
)
Dow Jones
45,960.11
(
-1.01%
)
Brent Oil
100.67
(
1.92%
)
Bitcoin
68,762.30
(
-3.56%
)
News Focus
News Focus
Post# of 257295
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122815
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 1728

Thursday, 07/08/2004 2:13:55 AM

Thursday, July 08, 2004 2:13:55 AM

Post# of 257295
Lucentis enrollment timeline slips for a third time:

According to Wednesday’s DNA CC, full enrollment for the phase-3 trial Lucentis in predominantly-classic AMD has now slipped from 1H04 (which actually means 2Q04) to “mid” 2004 (which means 3Q04) to 2H04 (which, of course, means 4Q04).

(The other phase-3 Lucentis trial, in minimally-classic/occult AMD completed enrollment behind its original schedule in late 2003.)

It seems that patients just don’t like getting poked in the eye every month, especially when some of the pokes result in serious inflammation.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today